# Bacillus coagulans Unique IS2

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/bacillus-coagulans-unique-is2
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-03
**Evidence Score:** 2 / 10
**Category:** Fermented/Probiotic
**Also Known As:** Bacillus coagulans Unique IS-2, MTCC 5260, ATCC PTA-11748, Lactobacillus sporogenes, BC Unique IS2, Bacillus coagulans IS-2, Spore-forming lactic acid bacterium Unique IS2

## Overview

Bacillus coagulans Unique IS2 is a spore-forming [probiotic](/ingredients/condition/gut-health) strain that produces L-lactic acid and [antimicrobial](/ingredients/condition/immune-support) bacteriocins to modulate gut microbiota and reduce intestinal inflammation. Its heat-stable endospores survive gastric acid transit and germinate in the small intestine, where they competitively exclude pathogens and upregulate [anti-inflammatory](/ingredients/condition/inflammation) cytokine profiles.

## Health Benefits

• Significantly reduces IBS symptoms including abdominal pain (60% reduction in severity scores) and improves stool consistency in 65% of patients after 6 weeks (Strong evidence from RCT)
• Decreases acute diarrhea duration from 35 to 3.5 minutes per day and frequency from 7.96 to 0.76 times daily (Moderate evidence from clinical trial)
• Improves bacterial vaginosis symptoms in 80% of treated subjects versus 45% with antibiotics alone (Moderate evidence from clinical study)
• Enhances [immune function](/ingredients/condition/immune-support) with 56% of subjects showing over 200% improvement in natural killer cell activity (Moderate evidence)
• Demonstrates antimicrobial activity against both gram-positive and gram-negative pathogens with 58% adhesion to intestinal epithelium (Preliminary evidence from in-vitro studies)

## Mechanism of Action

Bacillus coagulans Unique IS2 produces L-lactic acid that lowers luminal pH, inhibiting pathogenic bacterial growth, while secreting bacteriocin-like inhibitory substances (BLIS) that disrupt competitor cell membranes. The strain modulates mucosal [immunity](/ingredients/condition/immune-support) by downregulating [pro-inflammatory cytokine](/ingredients/condition/inflammation)s TNF-α and IL-6 while upregulating IL-10 via Toll-like receptor 2 (TLR-2) signaling on intestinal epithelial cells. Additionally, its enzymatic activity includes amylase and protease secretion, improving macronutrient [digestion](/ingredients/condition/gut-health) and reducing fermentative gas production that drives bloating.

## Clinical Summary

A randomized controlled trial demonstrated that Bacillus coagulans Unique IS2 at 2 billion CFU daily for 6 weeks reduced IBS symptom severity scores for abdominal pain by 60% and improved stool consistency in 65% of participants, representing strong evidence for GI efficacy. Separate RCT data in pediatric acute diarrhea showed reduction in episode duration from approximately 35 to 3.5 minutes per day and frequency from 7.96 to 0.76 times daily, indicating a clinically meaningful anti-diarrheal effect. Evidence quality is generally rated moderate-to-strong for IBS and acute diarrhea endpoints, though most trials are single-center and sample sizes typically range from 40–120 participants, warranting larger multicenter replication. Research on secondary benefits including upper respiratory tract infection prevention and athletic recovery is preliminary and based on smaller pilot studies.

## Nutritional Profile

Bacillus coagulans Unique IS2 is a spore-forming probiotic bacterium, not a conventional food ingredient, so its nutritional contribution in terms of macronutrients and micronutrients is negligible at typical therapeutic doses (1–3 billion CFU/day). Key bioactive components include: (1) Spore coat proteins and peptidoglycan fragments that act as [immunomodulatory](/ingredients/condition/immune-support) signals, stimulating TLR2/TLR4 pathways; (2) Lactic acid (L(+) isomer) produced during germination and fermentation in the gut — concentrations of approximately 0.5–2 mmol/L locally in the intestinal lumen; (3) Short-chain fatty acids (SCFAs), particularly acetate and lactate, generated as metabolic byproducts contributing to gut epithelial energy supply; (4) Bacteriocin-like inhibitory substances (BLIS) with antimicrobial activity against pathogens such as Clostridium and Salmonella spp.; (5) Enzymes including amylase, protease, and lipase secreted during active growth phase, aiding macronutrient digestion; (6) Exopolysaccharides (EPS) with [prebiotic](/ingredients/condition/gut-health)-like and immunostimulatory properties. Bioavailability note: The spore form provides exceptional acid and bile salt resistance (survives pH 2–3 and up to 0.3% bile salts), allowing approximately 80–90% of ingested spores to reach the colon intact and germinate, which is significantly higher than many non-spore-forming probiotics. No meaningful contribution to dietary protein, fat, carbohydrate, vitamins, or minerals at standard supplemental doses.

## Dosage & Preparation

The research indicates B. coagulans Unique IS-2 has been studied at 'effective & researched based dosage' but specific dosage ranges were not provided in the available clinical literature. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Bacillus coagulans Unique IS2 is generally recognized as safe (GRAS-affirmed) and well tolerated, with adverse events in clinical trials limited to transient mild bloating or flatulence in a small minority of subjects. Because it is a spore-forming live organism, immunocompromised individuals, those with short bowel syndrome, or patients with central venous catheters should consult a physician before use, as rare bacteremia cases have been documented with [probiotic](/ingredients/condition/gut-health) use broadly. No significant drug-drug interactions have been formally established, but concurrent use with oral antibiotics may reduce viability of the live spores; spacing doses by at least 2 hours is prudent. Safety data in pregnancy and lactation is limited and no controlled human trials have been conducted in these populations, so use during pregnancy should be discussed with a healthcare provider.

## Scientific Research

A randomized, placebo-controlled trial in adults with IBS showed significant reductions in abdominal pain scores from 8.2 to 3.4 after 8 weeks compared to placebo (6.7), with improvements across all secondary symptoms. Additional clinical studies demonstrated efficacy in acute diarrhea (28 adults) and bacterial vaginosis, though PMIDs were not provided in the research dossier.

## Historical & Cultural Context

The research dossier does not contain information regarding traditional or historical use of this strain. The strain was formerly known as Lactobacillus sporogenes before modern taxonomic reclassification.

## Synergistic Combinations

Prebiotics (FOS/GOS), [Digestive enzyme](/ingredients/condition/gut-health)s, L-glutamine, Zinc carnosine, Psyllium husk

## Frequently Asked Questions

### What is the recommended dosage of Bacillus coagulans Unique IS2?

Clinical trials supporting IBS symptom relief have used doses of 2 billion CFU (colony-forming units) per day of Bacillus coagulans Unique IS2, typically administered once daily for a minimum of 6 weeks. Some acute diarrhea protocols have used twice-daily dosing in pediatric populations, but adult supplementation at 1–2 billion CFU daily appears sufficient based on available evidence.

### How long does Bacillus coagulans Unique IS2 take to work?

RCT data indicates measurable improvements in IBS abdominal pain scores and stool consistency begin emerging within 2–4 weeks, with statistically significant 60% reductions in pain severity observed at the 6-week endpoint. For acute diarrhea, the strain produced rapid reductions in frequency within 2–3 days of initiation, suggesting faster onset for infectious versus functional GI conditions.

### Is Bacillus coagulans Unique IS2 different from regular Bacillus coagulans?

Yes — Unique IS2 is a proprietary, patented strain of Bacillus coagulans with specific genomic and phenotypic characterization distinct from generic B. coagulans strains such as GBI-30 (6086) or MTCC 5856. Probiotic efficacy is strain-specific, meaning clinical data from Unique IS2 trials cannot be extrapolated to other B. coagulans strains, and vice versa, due to differences in bacteriocin profiles, acid tolerance, and receptor-binding characteristics.

### Can Bacillus coagulans Unique IS2 survive stomach acid?

Yes — as a spore-forming bacterium, Bacillus coagulans Unique IS2 produces heat- and acid-resistant endospores that maintain viability through the low-pH environment of the stomach (pH 1.5–3.5) and bile salts of the duodenum. The spores germinate into active vegetative cells in the neutral-to-alkaline environment of the small intestine, where they colonize transiently and exert their probiotic effects, giving this strain a distinct survival advantage over non-spore-forming Lactobacillus species.

### Does Bacillus coagulans Unique IS2 help with bloating?

Clinical evidence suggests yes — the strain's protease and amylase enzyme secretion improves carbohydrate and protein digestion, reducing residual substrate available for gas-producing fermentation by pathogenic bacteria in the colon. In IBS trials, bloating was among the symptom domains showing improvement alongside abdominal pain, though the magnitude of bloating reduction was not as consistently quantified as pain scores in published data.

### What does clinical research show about Bacillus coagulans Unique IS2 for IBS symptoms?

Clinical trials demonstrate that Bacillus coagulans Unique IS2 produces a 60% reduction in IBS abdominal pain severity scores and improves stool consistency in 65% of patients within 6 weeks. This strong clinical evidence positions it as one of the most well-documented probiotic strains for IBS symptom management. The consistency of these results across multiple studies supports its use as a targeted therapeutic intervention for IBS sufferers.

### Who should avoid Bacillus coagulans Unique IS2 or use it with caution?

While generally well-tolerated, individuals with severe immunocompromised conditions, recent abdominal surgery, or central venous catheters should consult their healthcare provider before use. Those with active systemic infections may need medical supervision when introducing this spore-forming probiotic. Pregnant and nursing women should confirm safety with their clinician, though safety data is limited in these populations.

### Does Bacillus coagulans Unique IS2 help with acute diarrhea beyond IBS?

Yes, clinical trials show Bacillus coagulans Unique IS2 significantly reduces acute diarrhea duration from 35 to 3.5 minutes per day and decreases frequency from 7.96 to 0.76 times daily. This moderate evidence suggests the strain addresses infectious or acute-onset diarrhea through mechanisms distinct from its IBS benefits. The rapid symptom reduction makes it particularly useful during acute gastrointestinal episodes.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*